publication venue for
- Therapeutic targets and early stage clinical trials for pulmonary fibrosis. 28:19-28. 2019
- Polo-like kinases in AML. 21:1069-1074. 2012
- New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. 18:805-819. 2009
- Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. 18:311-325. 2009
- Beyond heparin and warfarin: the new generation of anticoagulants. 16:271-282. 2007
- Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?. 14:1009-1018. 2005
- Ximelagatran: the first oral direct thrombin inhibitor. 13:403-413. 2004
- Ximelagatran: the first oral direct thrombin inhibitor.. 13:403-413. 2004
- The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. 13:245-253. 2004
- Targeting cellular energy production in neurological disorders. 12:1655-1679. 2003
- Targeting cellular energy production in neurological disorders.. 12:1655-1679. 2003
- Novel strategies for systemic treatment of endometrial cancer. 9:2831-2853. 2000
- Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. 9:2215-2231. 2000
- Novel therapy for COPD. 9:3-23. 2000
- Novel therapy for asthma. 9:25-42. 2000
- L-arginine: a novel therapy for coronary artery disease?. 8:1785-1793. 1999
- AIT-082 as a potential neuroprotective and regenerative agent in stroke and central nervous system injury. 8:1255-1262. 1999
- AIT-082, a novel purine derivative with neuroregenerative properties. 6:1413-1417. 1997